Entering text into the input field will update the search result below

Our Take On Olema Pharmaceuticals


  • Shares of Olema Pharmaceuticals fell 60% after initial data on its estrogen receptor antagonist (OP-1250) failed to impress in a Phase 1a dose escalation study for breast cancer.
  • There is still a slither of hope as the doses chosen for the Phase 1b portion performed slightly better than competitors’ candidates, albeit from a small sample size (n=12).
  • With over $300 million in cash and some recent insider buying, this busted IPO merited further investigation.
  • A full investment analysis follows in the paragraphs below.
  • Looking for a portfolio of ideas like this one? Members of The Busted IPO Forum get exclusive access to our model portfolio. Learn More »

Young woman is having mammography examination at the hospital or private clinic with a professional female doctor.

Povozniuk/iStock via Getty Images

War is evil, but it is often the lesser evil.” – George Orwell

Today, we put a small biopharma concern that is already deep in 'Busted IPO' in the spotlight for the first time. A full analysis follows below.

Author's note: I present and update my best small-cap Busted IPO stock ideas only to subscribers of my exclusive marketplace, The Busted IPO Forum. Try a free 2-week trial today by clicking on our logo below!

This article was written by

Busted IPO Forum profile picture

The Busted IPO Forum is an investing group led by Bret Jensen, Chief Investment Strategist of Simplified Asset Management. Along with his team of analysts, Bret focuses on stocks that have been public for 18 months to 6 years, and that are significantly under their offering price.

The Busted IPO Forum: A model stock portfolio of attractive busted IPOs, trade alerts, deep dive analysis, a weekly option play idea and live chat.

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (4)

any bottom
Price. New lows any hope ???? @. @
Trying to picture what a " slither" of hope would look like!
Like a snake escaping into it's den?
(Just a gentle way to suggest a correction, Brett.)
@Nodelusionist1 You didn’t understand his comments. Had he put sliver, would you have understood?
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!

About OLMA

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on OLMA

Related Stocks

SymbolLast Price% Chg
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.